
The FDA approved asundexian with antiplatelet therapy after noncardioembolic ischemic stroke or high-risk TIA, based on OCEANIC-STROKE data.
Just ahead of the International Stroke Conference, the AHA released a scientific statement focusing on brain health and aimed at providing primary care providers an overview of factors influencing neurologic health.